Carl Zeiss Meditec Stock Current Asset
| CZMWF Stock | USD 61.22 0.01 0.02% |
Carl Zeiss Meditec fundamentals help investors to digest information that contributes to Carl Zeiss' financial success or failures. It also enables traders to predict the movement of Carl Pink Sheet. The fundamental analysis module provides a way to measure Carl Zeiss' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carl Zeiss pink sheet.
Carl |
Carl Zeiss Meditec Company Current Asset Analysis
Carl Zeiss' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Carl Zeiss Current Asset | 859 M |
Most of Carl Zeiss' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carl Zeiss Meditec is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Carl Zeiss Meditec has a Current Asset of 859 M. This is 60.08% lower than that of the Healthcare sector and 24.11% lower than that of the Medical Instruments & Supplies industry. The current asset for all United States stocks is 90.8% higher than that of the company.
Carl Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carl Zeiss' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Carl Zeiss could also be used in its relative valuation, which is a method of valuing Carl Zeiss by comparing valuation metrics of similar companies.Carl Zeiss is currently under evaluation in current asset category among its peers.
Carl Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 12.07 B | |||
| Shares Outstanding | 89.44 M | |||
| Shares Owned By Insiders | 59.10 % | |||
| Shares Owned By Institutions | 22.23 % | |||
| Price To Earning | 75.63 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 6.34 X | |||
| Revenue | 1.9 B | |||
| Gross Profit | 1.13 B | |||
| EBITDA | 419.49 M | |||
| Net Income | 293.91 M | |||
| Cash And Equivalents | 8.4 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 120.05 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.35 X | |||
| Book Value Per Share | 22.53 X | |||
| Cash Flow From Operations | 188.2 M | |||
| Earnings Per Share | 2.93 X | |||
| Price To Earnings To Growth | 3.93 X | |||
| Target Price | 138.8 | |||
| Number Of Employees | 4.22 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 12.53 B | |||
| Total Asset | 2.4 B | |||
| Retained Earnings | 458 M | |||
| Working Capital | 573 M | |||
| Current Asset | 859 M | |||
| Current Liabilities | 286 M | |||
| Z Score | 62.4 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 2.4 B | |||
| Last Dividend Paid | 1.1 |
About Carl Zeiss Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carl Zeiss Meditec's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carl Zeiss using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carl Zeiss Meditec based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Carl Pink Sheet
Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.